Copyright
©2008 The WJG Press and Baishideng.
World J Gastroenterol. Jan 7, 2008; 14(1): 114-119
Published online Jan 7, 2008. doi: 10.3748/wjg.14.114
Published online Jan 7, 2008. doi: 10.3748/wjg.14.114
Table 6 Histological grade and PPAR-γ and NF-κB expression
| Expression positivity (100%) | |||||
| I | II | III | IV | ||
| Initial points | n | 4 | 10 | 7 | 0 |
| NF-κB | 46.09-51.91 | 52.11-56.89 | 61.35-70.65 | 0 | |
| PPAR-γ | 31.57-39.93 | 24.54-29.06 | 16.30-20.55 | 0 | |
| Final points | n | 12 | 6 | 3 | 0 |
| NF-κB | 21.55-26.62 | 18.93-20.07 | 8.42-20.92 | 0 | |
| PPAR-γ | 37.20-44.97 | 49.82-56.51 | 55.50-69.84 | 0 | |
- Citation: Liang HL, Ouyang Q. A clinical trial of combined use of rosiglitazone and 5-aminosalicylate for ulcerative colitis. World J Gastroenterol 2008; 14(1): 114-119
- URL: https://www.wjgnet.com/1007-9327/full/v14/i1/114.htm
- DOI: https://dx.doi.org/10.3748/wjg.14.114